


Acanthamoeba keratitis



Eye Infection! Contact Lenses?

Think AK!

Acanthamoeba Keratitis (AK) in Europe:

A rare infectious disease—but increasing

>90% of cases are Contact Lens Wearers

Severe symptoms: eye pain, eye irritation, light sensitivity, tearing, vision loss, and redness.

Correct diagnosis is important

Early treatment is crucial for a good outcome

Misdiagnosed as herpes simplex keratitis in approximately 50% of cases!

Steroid treatment can result in worse outcomes.

Amoeba form cysts that resist conventional antimicrobial drugs

Can result in corneal transplant and enucleation.

No current licensed treatments for AK



The ODAK project, developing PHMB as a licensed drug for AK



ODAK

Orphan Drug for Acanthamoeba Keratitis

The ODAK project aims

- to develop PHMB as a new drug to treat AK
- to raise awareness of this rare disease.

Project update and results:

Retrospective study: PHMB 0.02% showed efficacy alone, or in combination with other anti-amoebics.

Preclinical work: completed.

Phase 1 Clinical Study: multiple dosing and doses of upto 0.08% PHMB were considered safe and tolerable.

Phase 3 Clinical Study: now recruiting to evaluate the efficacy, safety and tolerability of 0.08% PHMB solution compared to conventional combination therapy (0.02% PHMB + 0.1% propamidine). 130 patients with confirmed AK will be recruited in trial sites in the UK, Poland and Italy.

ODAK is a collaborative FP7 project.



Moorfields Eye Hospital **NHS**
NHS Foundation Trust



The research leading to these results has received funding through the European Community's Seventh Framework Programme under grant agreement No. 305661-2 (ODAK)